Annals
Established in 1927 by the American College of Physicians
:
Advanced search
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Summary for Patients
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box Social Bookmarking
 Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter
What's this?
box PubMed
Articles in PubMed by Author:
 arrow  Schramm, C.
space
 arrow  Lohse, A. W.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

BRIEF COMMUNICATION

Combined Therapy with Azathioprine, Prednisolone, and Ursodiol in Patients with Primary Sclerosing Cholangitis: A Case Series

right arrow Christoph Schramm, MD; Peter Schirmacher, MD; Ilka Helmreich-Becker, MD; Guido Gerken, MD; Karl Heinz Meyer zum Büschenfelde, MD, PhD; and Ansgar W. Lohse, MD

21 December 1999 | Volume 131 Issue 12 | Pages 943-946

Background: No established medical therapy alters the progressive course of primary sclerosing cholangitis.

Objective: To explore the potential usefulness of combined therapy with azathioprine, steroids and ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis.

Design: Case series.

Setting: University hospital in Mainz, Germany.

Patients: 15 patients with primary sclerosing cholangitis.

Intervention: Azathioprine (1 to 1.5 mg/kg of body weight per day), prednisolone (1 mg/kg per day initially, tapering to 5 to 10 mg per day) and UDCA (500 to 750 mg per day).

Measurements: Clinical and laboratory evaluation, liver biopsy, and endoscopic retrograde cholangiography (a >30% change in stenosis was considered significant).

Results: After a median observation period of 41 months (range, 3 to 81 months), liver enzyme levels declined significantly in all patients. Six of 10 patients with follow-up liver biopsies showed histologic improvement. Significant radiographic deterioration was seen in only 1 of 10 patients who had endoscopic retrograde cholangiography. In 7 patients previously treated with UDCA alone, liver enzyme levels declined significantly only after immunosuppressive therapy was added. Adverse drug reactions led to the withdrawal of study medications in 2 patients.

Conclusions: Combined immunosuppressive therapy may alter the progression of primary sclerosing cholangitis. Our observations suggest a benefit from adding immunosuppressive drugs to UDCA therapy. A randomized trial is warranted.

Author and Article Information
space

From Johannes Gutenberg University, Mainz, Germany.

Requests for Reprints: Ansgar W. Lohse, MD, I. Department of Medicine, Johannes Gutenberg-University, Langenbeckstrasse 1, 55131 Mainz, Germany. For reprint orders in quantities exceeding 100, please contact the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.

Current Author Addresses: Dr. Schirmacher: Department of Pathology, University of Cologne, Josef Stelzmann Strasse 9, 50931 Köln, Germany.

Dr. Gerken: Department of Gastroenterology and Hepatology, University of Essen, Hufelandstrasse 55, 45147 Essen, Germany.

Drs. Schramm, Helmreich-Becker, Meyer zum Büschenfelde, and Lohse: Department of Internal Medicine, University of Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany.

 

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related articles in Annals:

Summaries for Patients
Combination Therapy for Patients with Primary Sclerosing Cholangitis
Annals 1999 131: 943. [Full Text]  






 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 1999 by the American College of Physicians.